211 related articles for article (PubMed ID: 30388724)
1. Use of Growth Factors for Vulvo/Vaginal Bio-Stimulation.
Isaza PG
Surg Technol Int; 2019 May; 34():269-273. PubMed ID: 30388724
[TBL] [Abstract][Full Text] [Related]
2. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
4. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
5. The urogenital system and the menopause.
Calleja-Agius J; Brincat MP
Climacteric; 2015; 18 Suppl 1():18-22. PubMed ID: 26366796
[TBL] [Abstract][Full Text] [Related]
6. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
Edwards D; Panay N
Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
[TBL] [Abstract][Full Text] [Related]
7. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
8. Primavera: A new therapeutical approach to vulvo-vaginal atrophy.
Amori P; Di Nardo V; Vitiello G; Franca K; Hercogova J; Wollina U; Daaboul F; Tchernev G; Lotti T
Dermatol Ther; 2018 Nov; 31(6):e12678. PubMed ID: 30411455
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
10. Genitourinary syndrome of menopause and the use of laser therapy.
Hutchinson-Colas J; Segal S
Maturitas; 2015 Dec; 82(4):342-5. PubMed ID: 26323234
[TBL] [Abstract][Full Text] [Related]
11. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
12. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
13. Urogenital atrophy.
Calleja-Agius J; Brincat MP
Climacteric; 2009 Aug; 12(4):279-85. PubMed ID: 19387880
[TBL] [Abstract][Full Text] [Related]
14. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
Lev-Sagie A
Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
[TBL] [Abstract][Full Text] [Related]
15. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
16. Vaginal natural oxygenation device (VNOD) for concomitant administration of hyaluronic acid and topical hyperbaric oxygen to treat vulvo-vaginal atrophy: a pilot study.
Condemi L; Di Giuseppe J; Delli Carpini G; Garoia F; Frega A; Ciavattini A
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8480-8486. PubMed ID: 30556890
[TBL] [Abstract][Full Text] [Related]
17. Hormonal Medications for Genitourinary Syndrome of Menopause.
Pinkerton JV; Vaughan MH; Kaunitz AM
Clin Obstet Gynecol; 2024 Mar; 67(1):68-78. PubMed ID: 38032827
[TBL] [Abstract][Full Text] [Related]
18. An overview of chronic vaginal atrophy and options for symptom management.
Woods NF
Nurs Womens Health; 2012 Dec; 16(6):482-93; quiz 494. PubMed ID: 23253575
[TBL] [Abstract][Full Text] [Related]
19. Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.
Alvisi S; Baldassarre M; Gava G; Mancini I; Gagliardi M; Seracchioli R; Meriggiola MC
J Sex Med; 2018 Dec; 15(12):1776-1784. PubMed ID: 30446472
[TBL] [Abstract][Full Text] [Related]
20. Recognizing and treating urogenital atrophy in postmenopausal women.
Goldstein I
J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
